Ibex Receives CE Mark for AI Breast Cancer Solution
Ibex Medical Analytics, an AI-powered cancer diagnostics firm, has received the CE mark for the Galen Breast solution for use in supporting pathologists in detection of various types of breast cancer.
The solution is now generally available as Ibex partners with laboratories, hospitals and health systems to implement artificial intelligence (AI) technology into the diagnostic workflow. Galen Breast has already been ordered by multiple labs, including a network-wide deployment at a leading pathology group in Europe.
The CE mark follows pioneering results from a blinded, multi-site clinical study at Institut Curie in France and Maccabi Healthcare Services in Israel. Galen Breast demonstrated very high accuracy in detecting various types of breast cancer, including invasive and in-situ cancers, distinguishing between different types of invasive cancer (e.g., lobular versus ductal carcinoma) and grading of DCIS lesions.
Breast cancer is the most common malignant disease in women worldwide, with over two million new cases each year. As such, accurate and timely diagnosis of breast cancer is instrumental in guiding treatment decisions and improving patient survival rates. Over the last several years there has been an increase in the number of cancer cases and together with rapid advances in personalised medicine, this has resulted in increases in the complexity of cancer diagnosis. Coupled with a global decline in the number of pathologists, these trends have led to growing workloads imposed on pathology labs and health systems.
Ibex harnesses AI and machine learning technology and Galen Breast is an AI solution used for detection of breast cancer in pathology. It was developed utilising AI and machine learning techniques and was trained on hundreds of thousands of image samples, scanned from biopsy slides digitised using digital pathology. Galen Breast is already deployed in routine clinical practice at multiple pathology labs globally where it is used as a second read application for real-time quality control, helping pathologists improve diagnostic accuracy.
Anne Vincent-Salomon, director of pathology at Institut Curie and principal investigator of the study, said: “We are impressed with the successful study outcomes and performance of Galen Breast, which were in near perfect concordance with the consensus diagnosis between pathologists in distinguishing between malignant and benign biopsies, and between invasive and in-situ carcinoma and other histological types.
“Our team demonstrated that Ibex’s AI technology goes beyond detecting cancer and provides accurate insights on the type of tumour, the nuclear grading of in situ carcinomas and more. I’m confident that artificial intelligence will support breast pathologists and provide benefit to cancer patients across multiple segments of the diagnostic workflow and look forward to seeing this technology widely adopted in the field.”
Daphna Laifenfeld, chief scientific officer at Ibex Medical Analytics, added: “We are proud to have obtained this milestone CE Mark for our Galen Breast solution. The excellent results coming out of this study demonstrate the robustness of our Strong AI technology and enable us to offer pathologists an unprecedented breadth of features. We have secured multiple orders for Galen Breast from leading health systems in Europe, and we look forward to accelerating its deployment in the very near future.”